The effects of galactooligosaccharide (GOS) on peripheral insulin sensitivity and body weight control in obese adults with impaired glucose homeostasis - GOS and human substrate and energy metabolism

niversiteit Maastricht0 个研究点目标入组 46 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Overweight/obese (BMI * 28 kg/m2 < 40 kg/m2) insulin impaired men and post-menopausal women with impaired glucose tolerance (IGT: 2h plasma glucose during 75g OGTT 7.8-11.1 mmol/l) and/or impaired fasting glucose (plasma glucose * 5.6 mmol/l) aged 45-70 years will be included in the study.
•In addition, subjects have to be weight-stable for at least 3 months prior to participation (no change in bodyweight, i.e. < 3kg).

•Subjects will be excluded from participation when one or more of the following aspects are present:
•- diabetes mellitus
•- gastroenterological diseases or major abdominal surgery (allowed i.e.: appendectomy, cholecystectomy)
•- lactose intolerance and other digestive disorders
•- cardiovascular disease, cancer, liver or kidney malfunction (determined based on ALAT and creatinine levels, respectively)
•- disease with a life expectancy shorter than 5 years
•- abuse of products (alcohol consumption > 15 units/week, or any drugs)
•- excessive nicotine use defined as >20 cigarettes per day
•- plans to lose weight or follow a hypocaloric diet
•- regular supplement of pre- or probiotic products
•- intensive exercise more than three hours a week
•- - use of any medication that influences glucose or fat metabolism and inflammation, like i.e. *-blockers, lipid lowering-drugs (e.g. PPAR * or PPAR* (fibrates) agonists), glucose-lowering agents (including all sulfonylureas, biguanides, *-glucosidase inhibitors, thiazolidinediones, repaglinide, nateglinide and insulin), anti-oxidants or chronic corticosteroids treatment.
•- use of laxation products in the last three months or during the study period;- use of antibiotics in the last three months or during the study period.

发起方